| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Codex DNA (NASDAQ:DNAY) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Codex DNA beat estimated earnings by 1.96%, reporting an EPS of $-0.5 versus an estimate of $-0.51.
Revenue was up $2.80 million from the same period last year.
Last quarter the company missed on EPS by $0.0 which was followed by a 13.53% drop in the share price the next day.
Here's a look at Codex DNA's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.45 | -0.37 | -0.28 | |
| EPS Actual | -0.45 | -0.43 | -0.34 | -1.06 |
| Revenue Estimate | 3.90M | 3.83M | 2.93M | 2.55M |
| Revenue Actual | 5.64M | 3.08M | 2.79M | 2.85M |
To track all earnings releases for Codex DNA visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: DNAY
